Shane Jeffers, MD
Family Medicine · Groveport, OHNPI 1053707893
Payments from drug & device makers
Across 229 payments — averaging $42.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- AstraZeneca$1K
- Gilead$910
- Novo Nordisk$871
- Bayer$813
- GSK$664
- plus $4K from 29 others
What the payments were for
- Food & beverage$9,808100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 24 | $1,279 |
| AstraZeneca | 14 | $1,109 |
| Gilead | 9 | $910 |
| Novo Nordisk | 21 | $871 |
| Bayer | 13 | $813 |
| GSK | 28 | $664 |
| Abbott | 11 | $628 |
| AbbVie | 24 | $527 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $362 |
| Otsuka America Pharmaceutical, Inc. | 4 | $270 |
| Exact Sciences | 4 | $254 |
| Astellas Pharma US Inc | 8 | $249 |
| Idorsia Pharmaceuticals US Inc | 4 | $237 |
| Boehringer Ingelheim | 6 | $205 |
| Amgen(2 entities) | 6 | $201 |
| Phathom Pharmaceuticals, Inc. | 2 | $158 |
| Pfizer | 8 | $142 |
| Axsome Therapeutics, Inc. | 2 | $136 |
| Alkermes, Inc. | 2 | $135 |
| Merck | 3 | $121 |
| Dexcom, Inc. | 4 | $102 |
| Novartis | 3 | $70 |
| Sanofi-aventis U.S. LLC | 4 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $59 |
| Johnson & Johnson | 3 | $47 |
| Lundbeck LLC | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| Sanofi Pasteur Inc. | 2 | $27 |
| Ironwood Pharmaceuticals, Inc | 2 | $26 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Irhythm Technologies, Inc. | 1 | $15 |
| Renalytix AI, Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,828 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 112 | $171,944 |
| JardianceEmpagliflozin | 102 | $119,863 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 148 | $118,152 |
| EliquisApixaban | 106 | $112,731 |
| MounjaroTirzepatide | 38 | $52,689 |
| FarxigaDapagliflozin Propanediol | 33 | $47,786 |
| TrulicityDulaglutide | 34 | $41,150 |
| KerendiaFinerenone | 27 | $27,575 |
| ProliaDenosumab | 14 | $24,525 |
| VraylarCariprazine Hcl | 13 | $18,802 |
| XareltoRivaroxaban | 15 | $16,439 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $11,223 |
| MyrbetriqMirabegron | 18 | $10,996 |
| Atorvastatin Calcium | 608 | $6,128 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $6,007 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $871 | $171,944112 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $664 | $124,159159 claims |
| Boehringer IngelheimJardiance | $205 | $119,863102 claims |
| PfizerEliquis, Paxlovid | $142 | $115,435125 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,279 | $93,83972 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,109 | $59,01049 claims |
| BayerKerendia | $813 | $27,57527 claims |
| AmgenProlia | $201 | $24,52514 claims |
| AbbVieVraylar | $527 | $18,80213 claims |
| Johnson & JohnsonXarelto | $47 | $16,43915 claims |
| Astellas Pharma US IncMyrbetriq | $249 | $10,99618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Groveport
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.